Evidence map›Paper›PMID 40760154›Full record

ArticleScientific reports2025

Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma.

Vishwanath Kurawattimath, Barnabas Wilson, Kannoth Mukundan Geetha, Kalpana Divekar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vishwanath KurawattimathDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Harohalli, Kanakapura Road, Bengaluru, 562112, India.
Barnabas WilsonDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Harohalli, Kanakapura Road, Bengaluru, 562112, India. antrilparavai@gmail.com.
Kannoth Mukundan GeethaDepartment of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Harohalli, Kanakapura Road, Bengaluru, 562112, India.
Kalpana DivekarDepartment of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Harohalli, Kanakapura Road, Bengaluru, 562112, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) has a global occurrence of 0.59 to 3.69 per one lakh people. Palbociclib (Palbo), an inhibitor of CDK4 (cyclin dependent kinase) and CDK6, is used for treating cancer. Palbo showed a limited therapeutic effect in brains of transgenic mice after oral administration. Further, studies on P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) knock-out mice showed that P-gp and BCRP (efflux transporters) restrict Palbo's permeability across the blood-brain barrier (BBB). Hence, the clinical usefulness of Palbo for treating GBM is limited. Palbociclib-loaded nanoparticles of albumin (Nps-Bsa-Palbo) and palbociclib-loaded nanoparticles of albumin conjugated with Polysorbate 80 (Nps-Bsa-Palbo-Ps-80) were formulated and optimized using Design Expert

Indexed as

Antineoplastic AgentsBrain NeoplasmsGlioblastomaNanoparticlesPiperazinesPyridinesAnimalsBlood-Brain BarrierBrainCell Line, TumorDrug Delivery SystemsHumansMaleMiceRatsSerum Albumin, BovineAntineoplastic AgentspalbociclibPiperazinesPyridinesSerum Albumin, BovineAlbumin nanoparticlesBrain gliomaDesign of experimentPalbociclib

Identifiers

PMID40760154
PMCPMC12322058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.